Skip to main content
SpringerLink
Log in

Treatment of Advanced Breast Cancer with Tamoxifen

  • Chapter
Clinical Interest of Steroid Hormone Receptors in Breast Cancer

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 91))

Abstract

The overall response rate in advanced breast cancer patients treated with endocrine therapies is in the range of 30% [1, 2]. In recent years it has been demonstrated that response to various forms of endocrine treatment can be predicted in approximately 60% of cases provided that the patient’s tumor tissue contains the estrogen receptor (ER) protein [3]. This response rate is in the same range as that obtained with cytotoxic therapy [1, 2]. Furthermore, a response to endocrine therapy seems to predict that a response to subsequent cytotoxic treatment will be of longer duration and lead to prolonged survival [4, 5]. Another aspect of endocrine therapy is that new remissions can be achieved when using subsequent endocrine therapies [6–11]. Therefore, taking into account the fact that treatment of patients with metastatic disease is, at best, palliative, it appears that there is a sound clinical rationale behind the use of the relatively nontoxic endocrine treatment modalities.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Henderson IC, Canellos GP (1980) Cancer of the breast. N Engl J med 302: 17

    Article  PubMed  CAS  Google Scholar 

  2. Henderson IC, Canellos GP (1980) Cancer of the breast. N Engl J med 302: 78

    Article  PubMed  CAS  Google Scholar 

  3. McGuire WL, Pearson OH, Segalof A (1975) Predicting hormone responsivenes in human breast cancer. In: McGuire WL, Carbone PP, Vollmer EP (eds) Estrogen receptors in human breast cancer. Raven, New York, p 17

    Google Scholar 

  4. Legha SS, Buzdar AU, Smith TL, Swenerton KD, Hortobagyi GN, Blumenschein GR (1980) Response to hormonal therapy as a prognostic factor for metastatic breast cancer treated with combination chemotherapy. Cancer 46: 438

    Article  PubMed  CAS  Google Scholar 

  5. Manni A, Trujillo JE, Pearson OH (1980) Sequential use of endocrine therapy and chemotherapy for metastatic breast cancer: effects on survival. Cancer Treat Rep 64: 111

    PubMed  CAS  Google Scholar 

  6. Pearson OH, Ray DS (1959) A comparison of the results of adrenalectomy and hypophysectomy in carcinoma of the breast. In: Raven RW (ed) Cancer hormone therapy, vol 6. Butterworth, London, p 335

    Google Scholar 

  7. Manni A, Trujillo JE, Marshall JS, Brodkey J, Pearson OH (1979) Antihormone treatment of stage IV breast cancer. Cancer 43: 444

    Article  PubMed  CAS  Google Scholar 

  8. Manni A, Pearson OH, Brodkey J, Marshall JS (1979) Transsphenoidal hypophysectomy in breast cancer. Cancer 44: 2330

    Article  PubMed  CAS  Google Scholar 

  9. Manni A, Arafah BM, Pearson OH (1981) Androgen-induced remissions after antiestrogen and hypophysectomy in stage IV breast cancer. Cancer 48: 2507

    Article  PubMed  CAS  Google Scholar 

  10. Westerberg H (1980) Tamoxifen and fluoxymesterone in advanced breast cancer: a controlled clinical trial. Cancer Treat Rep 64: 117

    PubMed  CAS  Google Scholar 

  11. Smith IE, Harris AL, Morgan M, Ford HT, Gazet J-C, Harmer CL, White H, Parsons CA, Villardo A, Walsh G, McKinna J A (1981) Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. Br Med J 283: 1432

    Article  CAS  Google Scholar 

  12. Dao TL (1972) Ablation therapy for hormone-dependent tumours. Annu Rev Med 23: 1

    Article  PubMed  CAS  Google Scholar 

  13. Robin PE, Dalton GA (1977) The role of major endocrine ablation. In: Stoll BA (ed) Breast cancer management-early and late. Chicago Year Book, Chicago, p 147

    Google Scholar 

  14. Hayward J (1970) Hormones and human breast cancer. Springer, Berlin Heidelberg New York, pp 10, 33 (Recent results in cancer research, vol 24)

    Google Scholar 

  15. Dao TL (1978) The value of adrenalectomy in patients with metastatic breast cancer. Surg Clin North Am 58: 801

    PubMed  CAS  Google Scholar 

  16. Hayward JL, Atkins HJB, Falconer MA et al. (1970) Clinical trials comparing transfrontal hypophysectomy with adrenalectomy and with transethmoidal hypophysectomy. In: Joslin CAF, Gleave EN (eds) The clinical management of advanced breast cancer. Alpha Omega, Cardiff, p 50

    Google Scholar 

  17. Griffiths CT, Hall TC, Saba Z, Barlow JJ, Nevinny HB (1973) Preliminary trial of aminoglutethimide in breast cancer. Cancer 32: 31

    Article  PubMed  CAS  Google Scholar 

  18. Samojlik E, Santen RJ (1978) Adrenal suppression with aminoglutethimide. III. Comparison of plasma A4- and zl5-steroids in postmenopausal women treated for breast carcinoma. J Clin Endocrinol Metab 47: 717

    Article  PubMed  CAS  Google Scholar 

  19. Samojlik E, Veldhuis JD, Wells SA, Santen RJ (1980) Preservation of androgen secretion during estrogen suppresion with aminoglutethimide in the treatment of metastatic carcinoma. J Clin Invest 65: 602

    Article  PubMed  CAS  Google Scholar 

  20. Santen RJ, Worgul TJ, Samojlik E, Interrante A, Boucher AE, Lipton A, Harvey HA, White DS, Smart E, Cox C, Wells SA (1981) A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med 305: 545

    Article  PubMed  CAS  Google Scholar 

  21. Santen RJ, Santner S, Davis B, Veldhuis J, Samojlik E, Ruby E (1978) Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab 47: 1257

    Article  PubMed  CAS  Google Scholar 

  22. Lippman M, Bolan G, Hoff K (1976) The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 36: 4595

    PubMed  CAS  Google Scholar 

  23. Zava DT, McGuire WL (1978) Human breast cancer: androgen action mediated by estrogen receptor. Science 199: 787

    Article  PubMed  CAS  Google Scholar 

  24. Nicholson RL, Davies P, Griffiths K (1978) Interaction of androgens with oestradiol-17/? receptor proteins in DMBA-induced mammary tumours - a possible oncolytic mechanism. Eur J Cancer 14: 439

    Article  PubMed  CAS  Google Scholar 

  25. Lober J, Rose C, Salimtschik M, Mouridsen HT (1981) Treatment of advanced breast cancer with progestins. Acta Obstet Gynecol Scand [Suppl] 101: 39

    Article  CAS  Google Scholar 

  26. Santen RJ, Samojlik E (1979) Medical adrenalectomy for treatment of metastatic breast carcinoma. In: McGuire WL (ed) Breast cancer: advances in research and treatment, vol 3. Plenum, New York, p 79

    Google Scholar 

  27. Mouridsen HT, Palshof T, Patterson J, Battersby L (1978) Tamoxifen in advanced breast cancer. Cancer treat Rev 5: 131

    Article  PubMed  CAS  Google Scholar 

  28. Nicholson RI, Davies P, Griffiths K (1977) Effects of oestradiol-17/? and tamoxifen on nuclear oestradiol-17/3 receptors in DMBA-induced rat mammary tumours. Eur J Cancer 13: 201

    Article  PubMed  CAS  Google Scholar 

  29. Jordan VC, Dix CJ, Naylor KE, Prestwich G, Rowsby L (1978) Nonsteroidal antiestrogens: their biological effects and potential mechanism of action. J Toxicol Environ Health 4: 363

    Article  PubMed  CAS  Google Scholar 

  30. Koseki Y, Zava DT, Chamness GC, McGuire WL (1977) Estrogen receptor translocation and replenishment by the anti-estrogen tamoxifen. Endocrinology 101: 1104

    Article  PubMed  CAS  Google Scholar 

  31. Rochefort H, Borgma JL (1981) Differences between oestrogen receptor activation by oestrogen and anti-oestrogen. Nature 292: 257

    Article  PubMed  CAS  Google Scholar 

  32. Ip MM, Milholland RJ, Rosen F, Kim U (1981) Dichotomus effects of tamoxifen on a transplantable rat mammary tumour. Cancer Res 41: 984

    PubMed  CAS  Google Scholar 

  33. Butler WB, Kelsey WH (1981) Effect of the antiestrogen tamoxifen on synchronized cultures of MCF-7 cells. 17th Annual meeting Am Soc Clin Oncology, Abstr 35

    Google Scholar 

  34. Horwitz KB, Kosekiy, McGuire WL (1978) Estrogen control of progesterone receptor in human breast cancer: Role of estrodiol and antiestrogen. Endocrinology 103: 1742

    Article  PubMed  CAS  Google Scholar 

  35. Namer M, Lalanne C, Baulieu E-E (1980) Increase of progesterone receptor by tamoxifen as a hormonal challenge test in breast cancer. Cancer Res 40: 1750

    PubMed  CAS  Google Scholar 

  36. Sutherland RL, Murphy LC (1980) The binding of tamoxifen to human mammary carcinoma cytosol. Eur J Cancer 46: 1141

    Google Scholar 

  37. Sutherland RL, Murphy LC, Foo MS, Green MD, Whybourne AM, Krozowski ZS (1980) High- affinity anti-oestrogen binding site distinct from the oestrogen receptor. Nature 288: 273

    Article  PubMed  CAS  Google Scholar 

  38. Furr DJ, Patterson JS, Richardson DN, Slater SR, Wakeling AE (1979) Tamoxifen. In: Goldberg ME (ed) Pharmacological and biochemical properties of drug substances, vol 2. APA, Washington, p 355

    Google Scholar 

  39. Patterson JS (1981) Clinical aspects and development of antioestrogen therapy: A review of the endocrine effects of tamoxifen in animals and man. J Endocrinol 89: 67

    Google Scholar 

  40. Hayward JL, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A, Rubens RD (1977) Assesment of response to therapy in advanced breast cancer. Cancer 39: 1289

    Article  PubMed  CAS  Google Scholar 

  41. Tormey DC, Lippman MF, Edwards BE, Cassidy J (to be published) Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer

    Google Scholar 

  42. Tormey DC, Falkson G, Crowley J, Falkson HC, Voelkel J, Davies TE (1982) Dibromodulcitol and adriamycin ± tamoxifen in advanced breast cancer. Cancer Clin Trials 5: 33

    CAS  Google Scholar 

  43. Ingle JN, Ahmann DL, Green SJ, Edmondson JH, Bisel HF, Kvols LK, Nichols WC, Creagan ET, Hahn RG, Rubin J, Frytak S (1981) Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 304: 16

    Article  PubMed  CAS  Google Scholar 

  44. Beex L, Pieters G, Smals A, Koenders A, Benraad T, Kloppenborg P (1981) Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer. Cancer Treat Rep 65: 179

    PubMed  CAS  Google Scholar 

  45. Cocconi G, Lisi BD, Boni C, Mori P (1981) Chemotherapy vs combination of chemotherapy and endocrine therapy in advanced breast cancer. A prospective randomized study. UICO conf clin oncol breast cancer, Abstr. 03 - 0141

    Google Scholar 

  46. Fabian C, Sternson L, El-Serafi M, Cain L, Harne E (1981) Clinical pharmacology of tamoxifen in patients with breast cancer: correlation with clinical data. Cancer 48: 876

    Article  PubMed  CAS  Google Scholar 

  47. Ward HWC (1973) Anti-oestrogen therapy for breast cancer: A trial of tamoxifen at two-dose levels. Br Med J 1: 13

    Article  PubMed  CAS  Google Scholar 

  48. Kiang DT, Frenning DH, Vosika GJ, Kennedy BJ (1980) Comparison of tamoxifen and hypophysectomy in breast cancer treatment. Cancer 45: 1322

    Article  PubMed  CAS  Google Scholar 

  49. Stewart HJ, Forrest APM, Gunn JM, Hamilton T, Langlands AO, McFadyen IJ, Roberts MM (1980) The tamoxifen trial — A doubleblind comparison with stilbestrol in postmenopausal women with advanced breast cancer. Eur J Cancer [Suppl] 1: 83

    Google Scholar 

  50. Luporini G, Beratta G, Tabiadon D, Tedeschi L, Rossi A (1981) Comparison between oral medroxyprogesterone acetate (MPA) and tamoxifen (TMX) in advanced breast carcinoma. 17th Annual meeting Am Soc Clin Oncology, Abstr C-398

    Google Scholar 

  51. Mattsson W (1980) A phase III trial of treatment with tamoxifen versus treatment with high-dose medroxyprogesterone-acetate in advanced postmenopausal breast cancer. In: Iacobelli S, Marco AD (eds) Role of medroxyprogesterone in endocrine-related tumours. Raven, New York, p 65

    Google Scholar 

  52. Lipton A, Harvey HA, Santen RJ, Worgul T, Boucher A, White D (1981) Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. 17th Annual meeting Am Soc Clin Oncology, Abstr. C-437

    Google Scholar 

  53. Mouridsen HT, Salimtschik M, Dombernowsky P, Gelshoj K, Palshof T, Rorth M, Daehnfeldt JL, Rose C (1980) Therapeutic effect of tamoxifen versus combined tamoxifen and diethylstilbestrol in advanced breast cancer in postmenopausal women. Eur J Cancer [Suppl] 1: 107

    PubMed  Google Scholar 

  54. Carter AC, Sedransk N, Kelley RM, Ansfield FJ, Rawdin RG, Talley RW, Potter NR (1977) Diethylstilbestrol: Recommended dosages for different categories of breast cancer patients. JAMA 237: 2079

    Article  PubMed  CAS  Google Scholar 

  55. Mouridsen HT, Ellemann K, Mattsson W, Palshof T, Daehnfeldt JL, Rose C (1979) Therapeutic effect of tamoxifen versus tamoxifen combined with medroxyprogesterone acetate in advanced breast cancer in postmenopausal women. Cancer Treat Rep 63: 171

    PubMed  CAS  Google Scholar 

  56. Powles TJ (1981) Multiple endocrine therapy with tamoxifen, aminoglutethimide and danazol for treatment of patients with metastatic breast cancer. UICC conf clin oncology, Abstr 03 - 0106

    Google Scholar 

  57. Settatree RS, Butt WR, London DR, Holme GM, Morrison JM (1979) Tamoxifen and bromocriptine combination in advanced breast cancer. Advances in medical oncology. Research and education, vol 12. Pergamon, New York, p 806 (5)

    Google Scholar 

  58. Mouridsen HT, Palshof T, Engelsman E, Sylvester R (1980) CMF versus CMF + tamoxifen in advanced breast cancer in postmenopausal women. An EORTC trial. Int Congress Senology

    Google Scholar 

  59. Galmarini F, Santos R, Brunu R, Casas O, Chiesa J, Bertacchini C, D’Auria A, Domingoez E (1981) Tamoxifen + CIVEFU vs CIVEFU in advanced breast cancer. UICC conf oncology, Abstr 03 - 0359

    Google Scholar 

  60. Boccardo F, Rubagotti A, Sertoli MR, Rosso R (1981) Randomized trial of chemo-hormone therapy in advanced breast cancer. 17th Annual meeting Am Soc Clin Oncology, Abstr. C397

    Google Scholar 

  61. Arraztora J, Ramirez G (1981) Chemotherapy with and without hormonal manipulation in the treatment of advanced breast cancer. 17th Annual meeting Am Soc Clin Oncology, Abstr C-401

    Google Scholar 

  62. Pritchard KI, Thomson DB, Meakin JW, Myers RE, Sutherland DJA, Mobbs VG, Campbell J (1981) The role of tamoxifen in premenopausal women with metastatic carcinoma of the breast: an update. 17th Annual meeting Am Soc Clin Oncology, Abstr C-405

    Google Scholar 

  63. Wada T, Koyama H, Terasawa T (1981) Effect of tamoxifen in premenopausal Japanese women with advanced breast cancer. Cancer Treat Rep 65: 728

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology I, Finsen Institute, 49 Strandboulevarden, 2100, Copenhagen, Denmark

    C. Rose & H. T. Mouridsen

Authors
  1. C. Rose
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. T. Mouridsen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institute Jules Bordet, Centre des Tumeurs, Service de Medicine, Clinique et Laboratoire de Cancerologie Mammaire, l’Université Libre de Bruxelles, Rue Héger-Bordet 1, 1000, Bruxelles, Belgium

    G. Leclercq , R. Paridaens  & J. C. Heuson ,  & 

  2. Istituto per lo Studio e la Cura dei Tumori, Istituto di Oncologia Sperimentale e Clinica dell’Università, Istituto Nazionale per la Ricerca sul Cancro, Viale Benedetto XV n. 10, 16132, Genova, Italy

    S. Toma

Rights and permissions

Reprints and permissions

Copyright information

© 1984 Springer-Verlag Berlin · Heidelberg

About this chapter

Cite this chapter

Rose, C., Mouridsen, H.T. (1984). Treatment of Advanced Breast Cancer with Tamoxifen. In: Leclercq, G., Toma, S., Paridaens, R., Heuson, J.C. (eds) Clinical Interest of Steroid Hormone Receptors in Breast Cancer. Recent Results in Cancer Research, vol 91. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-82188-2_33

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-82188-2_33

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-82190-5

  • Online ISBN: 978-3-642-82188-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation